Skip to content
Clinical Trials – home

Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.

Verified siteinfo

Poland Ul. Tadeusza Szafrana 5d / U2-U5, 30-363 Cracow, Poland

  • 41 trials recruiting
  • Colitis ulcerative · Crohn's disease · Systemic lupus erythematosus
  • Adults and children

About Specializations

Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k. in Cracow, Poland specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Systemic lupus erythematosus, Sjogren's syndrome, and other specialisations. This site conducts important research.

Main research areas of the site

Inflammatory Bowel Disease Research

The gastroenterology department at Centrum Medyczne Plejady focuses on Inflammatory Bowel Disease, testing new therapeutic approaches aimed at achieving clinical remission and improving quality of life for patients.

  • Crohn's disease – evaluation of novel biologics and small molecules
  • Ulcerative colitis – assessment of induction and maintenance strategies
  • Endoscopic response as a marker of treatment success
  • Patient‑reported outcomes for disease activity

With a robust portfolio of 84 trials, the site collaborates with investigators to advance care for individuals living with chronic intestinal inflammation.

Autoimmune and Systemic Disease Trials

Research at the center targets autoimmune and systemic disorders, seeking to modulate immune pathways and reduce disease burden across a spectrum of conditions.

  • Systemic lupus erythematosus – testing targeted immunomodulators
  • Sjögren’s syndrome – improving glandular function and systemic symptoms
  • Systemic sclerosis – evaluating antifibrotic agents
  • Biomarker‑driven patient selection for personalized therapy

The department’s multidisciplinary team leverages its experience to explore long‑term safety and efficacy of emerging treatments.

Dermatology and Skin Research

The clinic conducts trials in dermatology to address inflammatory and chronic skin conditions, aiming to provide patients with more effective and tolerable options.

  • Psoriatic arthritis – comparative studies of biologic agents
  • Atopic dermatitis – long‑term safety of biologics in children
  • Acne vulgaris – topical therapies for sustained clearance
  • Chronic spontaneous urticaria – novel antihistamine‑refractory treatments

Participants benefit from state‑of‑the‑art assessments of disease activity and quality‑of‑life measures.

Neurology and Movement Disorder Studies

Investigations in the neurological field focus on migraine, Parkinson's disease, and epilepsy, evaluating new drugs and delivery methods to lessen symptom severity and improve daily functioning.

  • Migraine – preventive and acute therapies for adolescents
  • Parkinson's disease – agents targeting tremor and disease progression
  • Dravet syndrome – adjunctive treatments to reduce seizure frequency
  • Lennox‑Gastaut syndrome – combination therapies for refractory seizures

The site’s neurologic expertise supports rigorous safety monitoring and functional outcome assessments.

Allergy and Respiratory Research

Trials address allergic rhinitis and related respiratory conditions, testing immunotherapy and symptom‑relief strategies for seasonal and perennial triggers.

  • Birch pollen‑induced allergic rhinoconjunctivitis – sublingual immunotherapy efficacy
  • Grass pollen allergy – pediatric safety and long‑term benefit
  • Seasonal allergic rhinitis – quality‑of‑life impact
  • H1 antihistamine‑refractory chronic urticaria – novel biologic options

By integrating allergen challenge models, the center contributes valuable data on disease control across age groups.

Cardiovascular and Metabolic Trials

The facility also explores cardiovascular and metabolic health, aiming to lower risk factors and improve outcomes for patients with established disease.

  • Atherosclerotic cardiovascular disease – LDL‑cholesterol lowering interventions
  • Obesity – lifestyle‑adjunct pharmacologic studies
  • Metabolic syndrome – combined therapy assessments
  • Cardiovascular event reduction – long‑term safety monitoring

The research integrates cardiovascular endpoints with metabolic parameters to provide a comprehensive view of patient health.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Tadeusza Szafrana 5d / U2-U530-363 CracowPoland
Recruiting now
41 trials
Conditions studied
44
Partner status
Verified site

More sites in CracowPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

114 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.

Study of SPN-817 (Huperzine A) in Adults with Focal Onset Seizures: Testing Safety and Effectiveness of Treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Huperzine A
  • Sponsor:Supernus Pharmaceuticals Inc.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.